Senomorphics vs Senolytics: Two Strategies for Dealing With Zombie Cells (2026)

You have a house with a broken pipe leaking into the walls. You could rip out the pipe and replace it. Or you could seal the leak and leave the pipe in place.

Both solve the immediate problem -- water damage. But they solve it differently, with different risks, different costs, and different failure modes. The pipe-replacement approach is more definitive but more disruptive. The sealing approach is gentler but requires ongoing maintenance and trusts that the sealed pipe won't fail elsewhere.

This is the core tension in one of the most active debates in aging research: what to do about senescent cells. Two classes of interventions have emerged. Senolytics kill senescent cells outright -- rip out the pipe. Senomorphics suppress the toxic secretions of senescent cells without killing them -- seal the leak.

Both strategies work in animal models. Both have compounds in human clinical trials. And increasingly, researchers believe the real answer involves both.

TL;DR -- Key Takeaways

• Senescent ("zombie") cells damage tissues primarily through their SASP -- a cocktail of inflammatory molecules they constantly secrete
• Senolytics (fisetin, quercetin + dasatinib, navitoclax) kill senescent cells by targeting anti-apoptotic survival pathways (BCL-2/BCL-XL, PI3K/AKT, p53/p21)
• Senomorphics (rapamycin, metformin, ruxolitinib, apigenin) suppress the SASP without killing the cell, targeting NF-kB, mTOR, and JAK/STAT signaling
• Senolytics use pulse dosing (e.g., 2 consecutive days per month); senomorphics use continuous low-dose regimens
• Unity Biotechnology's UBX1325 (a BCL-xL inhibitor for macular degeneration) is the most advanced senolytic in clinical trials
• Neither approach is universally superior -- senolytics are more definitive but carry disruption risk; senomorphics are gentler but require ongoing use
• Combination protocols (periodic senolytic pulses + daily senomorphic maintenance) are emerging as the leading research framework

The Senescent Cell Problem: A Quick Recap

If you have read Senescent Cells Explained, you know the basics. If not, here is the condensed version.

A senescent cell is a cell that has sustained enough damage -- from DNA breaks, telomere erosion, oxidative stress, or oncogene activation (when a gene that normally promotes cell growth becomes permanently switched on) -- to permanently exit the cell cycle. It stops dividing. But unlike a cell that undergoes apoptosis (programmed cell death, the orderly self-destruction process cells use to eliminate themselves when damaged), a senescent cell refuses to die.

In youth, this is largely protective. Halting a damaged cell's division prevents it from becoming cancerous. The immune system -- specifically natural killer cells (immune cells specialized in destroying abnormal cells) and macrophages (immune cells that engulf and digest cellular debris) -- recognizes and clears these cells efficiently.

The problem is aging. Senescent cells accumulate faster than the immune system can clear them. By age 60-80, they may represent 5-15% of cells in some tissues (Tuttle et al., Aging Cell, 2020; PMID 31560839).

The real damage is not the cells themselves. It is what they secrete.

The SASP: Why Zombie Cells Are Dangerous

Senescent cells produce a toxic cocktail called the SASP (Senescence-Associated Secretory Phenotype) -- a mixture of pro-inflammatory cytokines (IL-6, IL-1beta, TNF-alpha), chemokines (signaling proteins that recruit immune cells to the area), matrix metalloproteinases (MMPs -- enzymes that degrade the structural scaffolding between cells), and growth factors.

The SASP is the mechanism of harm. It:

• Drives chronic systemic inflammation -- the "inflammaging" that underlies cardiovascular disease, neurodegeneration, and metabolic dysfunction
• Damages neighboring healthy cells and degrades the extracellular matrix (the structural network that holds tissues together)
• Induces paracrine senescence -- the SASP from one senescent cell can push nearby healthy cells into senescence, creating a spreading wave of dysfunction (Acosta et al., Cell, 2013; PMID 23540693)
• Impairs stem cell function and tissue regeneration

Xu et al. (2018) demonstrated this causally: transplanting a small number of senescent cells into young mice was sufficient to spread senescence throughout the body and reduce lifespan (Nature Medicine, 2018; PMID 29988130). Earlier, Baker et al. (2016) showed that genetically clearing senescent cells extended lifespan in mice (Nature, 2016; PMID 26840489).

So you have a clear target: the SASP. The question is how to neutralize it.

Two answers have emerged. Kill the cells producing it. Or shut down the production without killing the cells.

What Are Senolytics?

Senolytics are compounds that selectively induce apoptosis (programmed cell death) in senescent cells while sparing healthy cells. The term was coined in 2015 by Drs. James Kirkland and Tamara Tchkonia at the Mayo Clinic, from the Latin senex (old) and Greek lytic (destroying) (Zhu et al., Aging Cell, 2015; PMID 25754370).

The foundational insight was this: senescent cells are not immortal by accident. They actively resist death by upregulating specific survival pathways -- what researchers call SCAPs (Senescent Cell Anti-apoptotic Pathways). These are the molecular shields that keep zombie cells alive despite being damaged and non-functional. Block those shields, and the cell's own internal death machinery finishes the job.

How Senolytics Work: The Three Key Pathways

1. BCL-2/BCL-XL Anti-Apoptotic Proteins

The BCL-2 family of proteins acts as a molecular brake on apoptosis. Normal cells maintain a balanced ratio of pro-apoptotic (pro-death) and anti-apoptotic (pro-survival) BCL-2 family members. Senescent cells tip this balance heavily toward survival by overexpressing BCL-2 and BCL-XL (a closely related anti-apoptotic protein).

Navitoclax (ABT-263), developed originally as a cancer drug, is a BH3 mimetic -- it mimics the natural "death signal" proteins that bind BCL-2 and BCL-XL, blocking their protective function. When BCL-XL is neutralized, the senescent cell's pro-apoptotic machinery activates, and the cell undergoes apoptosis (Zhu et al., Aging Cell, 2016; PMID 26711051).

The limitation: navitoclax also inhibits BCL-XL in platelets (the blood cells responsible for clotting), causing dose-dependent thrombocytopenia (low platelet count). This is why it remains a research tool and why next-generation senolytic drugs target BCL-XL more selectively.

2. PI3K/AKT Survival Signaling

The PI3K/AKT pathway is a master regulator of cell survival, growth, and metabolism. In senescent cells, this pathway is constitutively active -- permanently switched on -- providing a continuous survival signal that overrides the apoptosis triggers these damaged cells would normally receive.

Fisetin targets this pathway. In the landmark Mayo Clinic screen of ten flavonoids, fisetin ranked first for senolytic potency, outperforming quercetin, luteolin, curcumin, and six others (Yousefzadeh et al., EBioMedicine, 2018; PMID 30279143). It inhibits PI3K/AKT signaling upstream of BCL-2, collapsing the survival network from a different angle than direct BCL-2 inhibitors.

Quercetin works through a similar but not identical mechanism, and is most studied in combination with dasatinib (a tyrosine kinase inhibitor originally developed for leukemia). The quercetin + dasatinib (D+Q) combination was the first senolytic regimen tested in humans (Hickson et al., EBioMedicine, 2019; PMID 31542391).

3. p53/p21 Checkpoint Regulation

The p53 protein is often called the "guardian of the genome." When a cell sustains DNA damage, p53 activates p21, which halts the cell cycle to allow repair. If damage is irreparable, p53 normally triggers apoptosis.

In senescent cells, this system is stuck in an intermediate state: p53/p21 signaling is active enough to halt division permanently, but not active enough to trigger death. Some senescent cell subpopulations depend on sustained p21 expression for survival. Compounds that modulate this checkpoint -- either by reactivating p53's pro-apoptotic function or by destabilizing the p21-dependent survival state -- can selectively kill these cells.

FOXO4-DRI, a peptide that disrupts the interaction between FOXO4 (a protein that sequesters p53 away from the cell's apoptosis machinery) and p53, restored p53-mediated apoptosis in senescent cells in mice, improving fitness, fur density, and kidney function (Baar et al., Cell, 2017; PMID 28340339).

Key Senolytic Compounds

Key Takeaway: Senolytics kill senescent cells by disrupting their survival pathways (BCL-2 family, PI3K/AKT). The most potent natural senolytics — fisetin and the dasatinib + quercetin combination — have been validated in both animal models and early human trials. The "hit and run" approach (high-dose pulse, then weeks of no treatment) matches the biology: cleared cells take weeks to reaccumulate.

What Are Senomorphics?

Senomorphics (also called senostatics) take the opposite approach. Instead of killing senescent cells, they suppress the SASP -- silencing the inflammatory output without eliminating its source. The term was introduced by Kirkland and Tchkonia in the same body of work that defined senolytics, to distinguish compounds that modulate senescent cell behavior from those that destroy the cells.

The logic: if the SASP is the mechanism of harm, perhaps you do not need to kill the cell. You just need to shut it up.

How Senomorphics Work: The Three Key Pathways

1. NF-kB Signaling

NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells) is the master transcription factor controlling inflammatory gene expression. It is the single most important driver of the SASP. In senescent cells, NF-kB is constitutively active, driving continuous production of IL-6, IL-8, IL-1beta, TNF-alpha, and dozens of other SASP factors.

Blocking NF-kB suppresses the SASP dramatically. Metformin, the widely prescribed diabetes drug, inhibits NF-kB activity through AMPK activation (AMP-activated protein kinase -- a cellular energy sensor that, when activated, shifts the cell from growth mode to conservation mode). In senescent human fibroblasts, metformin reduced SASP cytokine secretion by 40-60% without affecting cell viability (Moiseeva et al., Aging Cell, 2013; PMID 23834033).

Apigenin, a flavonoid found in chamomile, parsley, and celery, also inhibits NF-kB-driven SASP production. A 2015 study demonstrated that apigenin suppressed IL-6 and IL-8 secretion in senescent human fibroblasts through direct NF-kB inhibition, without killing the cells or reversing the senescent state (Lim et al., J Cell Physiol, 2015; PMID 25303541).

2. mTOR Pathway

mTOR (mechanistic target of rapamycin) is a nutrient-sensing kinase (an enzyme that adds phosphate groups to other proteins) that integrates signals about nutrient availability, growth factors, and energy status. When mTOR is active, it promotes cell growth, protein synthesis, and -- in senescent cells -- SASP production.

The connection between mTOR and the SASP was established by Laberge et al. (2015), who showed that rapamycin (the canonical mTOR inhibitor, originally discovered as an antifungal compound from Easter Island soil bacteria) suppressed the translation of SASP components, particularly IL-6, by inhibiting the mTORC1 complex. Crucially, rapamycin reduced SASP secretion by 50-70% without reversing senescence or killing the cell (Nature Cell Biology, 2015; PMID 26147250).

This finding reframed rapamycin -- already the most replicated lifespan-extending drug in mammals -- as a senomorphic agent. Part of rapamycin's life-extension effect may come from suppressing the inflammatory output of accumulated senescent cells rather than from its better-known effects on autophagy and protein quality control.

Everolimus, a rapamycin analog (rapalog), demonstrated this clinically. In a randomized human trial of elderly volunteers, low-dose everolimus improved immune function by approximately 20% -- an effect attributed partly to reduced inflammatory signaling from senescent immune cells (Mannick et al., Science Translational Medicine, 2014; PMID 25540326).

3. JAK/STAT Signaling

The JAK/STAT pathway (Janus kinase / Signal Transducer and Activator of Transcription) is the signaling cascade through which many inflammatory cytokines exert their effects. When IL-6 or other SASP factors bind to cell surface receptors, JAK enzymes activate STAT transcription factors, which enter the nucleus and drive expression of more inflammatory genes. In senescent cells, this creates a self-reinforcing loop: the SASP activates JAK/STAT, which drives more SASP production.

Ruxolitinib, an FDA-approved JAK1/JAK2 inhibitor used for myelofibrosis (a bone marrow cancer) and graft-versus-host disease, was shown to suppress the SASP and reduce senescent cell burden in aged mice. Xu et al. (2015) demonstrated that ruxolitinib improved adipose tissue function, reduced circulating inflammatory markers, and enhanced physical function in old mice -- effects comparable to genetic senescent cell clearance (Aging Cell, 2015; PMID 26166558).

The significance: ruxolitinib is already FDA-approved and well-characterized. Its senomorphic activity was a secondary discovery, but it provides proof of principle that JAK/STAT inhibition can reduce the systemic harm of senescent cells in a living organism.

Key Senomorphic Compounds

Mechanism Comparison: Senolytics vs Senomorphics

The Clinical Pipeline: Where Things Stand in 2026

Senolytics in Human Trials

Dasatinib + Quercetin (D+Q) -- Mayo Clinic

The D+Q combination was the first senolytic tested in humans. The initial open-label trial in patients with diabetic kidney disease demonstrated reduced senescent cell burden in adipose tissue and skin, decreased circulating SASP factors (IL-6, MMP-9, MMP-12), and improved metabolic markers after just 3 days of dosing -- effects that persisted at least 11 days after the last dose (Hickson et al., EBioMedicine, 2019; PMID 31542391).

A parallel first-in-human study in idiopathic pulmonary fibrosis (IPF -- a progressive lung disease driven partly by senescent cell accumulation) demonstrated improved physical function after a brief D+Q course (Justice et al., EBioMedicine, 2019; PMID 30616998).

Multiple Phase 2 trials are now running or completed across Mayo Clinic, Wake Forest, and other institutions, testing D+Q in Alzheimer's disease, frailty, bone marrow transplant survivors, and chronic kidney disease.

Fisetin -- Mayo Clinic (AFFIRM-LITE)

The AFFIRM-LITE trial (NCT03675724) tests 20 mg/kg/day of fisetin for 2 consecutive days in adults aged 70-90, measuring senescence biomarkers (p16, p21), inflammatory markers, and physical function. Led by Dr. James Kirkland, this is the most watched natural senolytic trial in the field. Results have not been published as of March 2026. Additional fisetin trials are enrolling for vascular function, frailty, and healthy volunteer pharmacokinetics.

Unity Biotechnology -- UBX1325 (Foselutoclax)

Unity Biotechnology represents the pharmaceutical senolytic approach. Their lead compound, UBX1325 (now known as foselutoclax), is a small-molecule BCL-xL inhibitor designed for intravitreal injection (injection directly into the eye) to treat age-related macular degeneration (AMD) and diabetic macular edema (DME).

The Phase 1 BEHOLD trial demonstrated that a single intravitreal injection of UBX1325 improved best-corrected visual acuity in patients with advanced DME, with effects lasting 24 weeks from a single dose -- consistent with the senolytic principle that you clear a cohort of senescent cells and the benefit persists until new ones accumulate (Unity Biotechnology, 2022, BEACON Phase 2 results).

The Phase 2 BEACON trial in DME confirmed dose-dependent improvements in visual acuity. Unity is now advancing toward pivotal Phase 2b/3 trials.

The UBX1325 program is important because it is the clearest clinical demonstration that senolytics work in humans -- that selectively killing senescent cells in a specific tissue produces measurable functional improvement. The limitation is that it is local delivery (eye injection), not systemic.

Senomorphics in Human Trials

Metformin -- TAME Trial

The TAME (Targeting Aging with Metformin) trial, led by Dr. Nir Barzilai at the Albert Einstein College of Medicine, is the most ambitious aging trial ever designed. It is a multicenter Phase 3 study testing whether metformin delays the onset of age-related diseases (cardiovascular disease, cancer, dementia, mortality) in 3,000 adults aged 65-79.

TAME is not framed as a senomorphic trial, but metformin's mechanisms include AMPK-mediated NF-kB suppression, which reduces SASP output from senescent cells. If TAME succeeds, it would be the first trial to demonstrate that a pharmaceutical intervention can slow aging as a biological process rather than treating individual diseases. The trial began enrollment in 2024 and results are expected in the late 2020s.

Rapamycin / Everolimus

The Mannick et al. (2014) trial demonstrated that low-dose everolimus improved immune function in elderly volunteers. Follow-up studies confirmed that intermittent low-dose rapamycin analogs enhanced vaccine responses and reduced infection rates in older adults (Mannick et al., Science Translational Medicine, 2018; PMID 30068573).

The PEARL (Participatory Evaluation of Aging with Rapamycin for Longevity) trial, among others, is evaluating low-dose rapamycin for aging biomarkers. These trials test rapamycin's senomorphic properties alongside its effects on autophagy, protein homeostasis, and immune function.

Ruxolitinib

No dedicated aging trial exists for ruxolitinib yet, but the preclinical data from Xu et al. (2015) -- showing that JAK inhibition reduced senescent cell burden and improved physical function in aged mice -- has generated interest. Several academic groups have proposed pilot studies.

Head-to-Head: The Kill vs Suppress Debate

The Case for Senolytics (Killing)

1. Permanence. When you kill a senescent cell, its SASP stops permanently. The benefit lasts until new senescent cells accumulate -- weeks to months. Senomorphics require continuous dosing, and the SASP resumes when you stop.

2. Complete elimination. Senescent cells do more than secrete the SASP. They physically occupy space in tissues, compete for nutrients and oxygen, and may impair the function of neighboring cells through direct contact signaling. Killing them frees the niche for healthy or progenitor cells.

3. No suppression escape. A suppressed senescent cell is still a damaged cell. It can mutate further, evolve resistance to senomorphic suppression, or reactivate SASP components through alternative pathways. A dead cell has zero pathological potential.

4. The Baker proof. The most dramatic demonstrations of benefit from targeting senescent cells -- the Baker et al. studies showing 17-35% lifespan extension in mice -- used genetic ablation (complete killing), not suppression.

The Case for Senomorphics (Suppression)

1. Some senescent cells may be beneficial. Senescent cells play roles in wound healing, tissue remodeling, embryonic development, and tumor suppression. The SASP itself recruits immune cells for tissue repair in acute injury contexts. Blanket killing of all senescent cells could impair these protective functions. Senomorphics preserve the cell's structural presence and non-SASP functions while silencing the harmful output.

This concern is not theoretical. Demaria et al. (2014) showed that eliminating senescent cells during wound healing in mice significantly delayed tissue repair (Developmental Cell, 2014; PMID 25449471). Senescent fibroblasts secrete PDGF-AA (platelet-derived growth factor) that accelerates wound closure -- kill them, and wounds heal slower.

2. Gentler risk profile. Senolytics that target BCL-2/BCL-XL (navitoclax, UBX1325) can damage healthy cells that depend on these survival proteins -- most notably platelets. Senomorphics work on signaling pathways, not survival pathways, and generally have lower acute toxicity.

3. Continuous protection. Senescent cells are constantly being generated -- from exercise-induced muscle damage, UV exposure, metabolic stress, and normal tissue turnover. A daily senomorphic provides continuous SASP suppression. Senolytics leave a gap between doses when newly formed senescent cells can produce SASP unchecked.

4. Established safety profiles. Metformin and rapamycin have decades of human safety data. Metformin has been taken daily by hundreds of millions of diabetic patients. Low-dose rapamycin has growing safety data from aging trials. Most senolytics are either experimental (navitoclax, UBX1325) or have limited human data at senolytic-relevant doses (fisetin, D+Q).

The Tradeoff: Clearance vs Suppression

The fundamental tradeoff comes down to this:

Senolytics trade potency for intermittency. They hit hard but leave gaps. During those gaps, new senescent cells form and produce SASP freely.

Senomorphics trade permanence for continuity. They provide constant coverage but never eliminate the source. Stop taking them, and you are back to baseline -- potentially worse than baseline if senescent cells continued accumulating during the suppression period.

Neither approach alone is theoretically complete. This is why the field is converging on combination strategies.

Key Takeaway: Senomorphics suppress SASP (the inflammatory secretions from senescent cells) without killing the cells themselves. Apigenin, rapamycin, and metformin all have senomorphic properties. The advantage: continuous low-dose treatment with lower risk. The disadvantage: the senescent cells remain, and SASP suppression must be maintained indefinitely.

Combination Approaches: The Emerging Consensus

The most sophisticated current thinking treats senescent cell management as a two-phase problem:

Phase 1: Periodic clearance (senolytics). Use pulse dosing to clear the existing senescent cell burden. This reduces the total number of SASP-producing cells and creates a lower baseline.

Phase 2: Continuous suppression (senomorphics). Between senolytic pulses, use daily senomorphic compounds to suppress the SASP output from whatever senescent cells remain or newly form.

This is analogous to cancer treatment: debulking surgery (senolytics) followed by maintenance chemotherapy (senomorphics).

Evidence for Combination Benefit

Xu et al. (2018) provided some of the earliest evidence that combining senolytic and senomorphic approaches could be synergistic. In aged mice, intermittent D+Q treatment combined with continuous JAK inhibition produced greater improvements in physical function and greater reductions in circulating inflammatory markers than either approach alone (Nature Medicine, 2018; PMID 29988130).

The logic is straightforward: senolytics reduce the denominator (total senescent cells), and senomorphics reduce the numerator (SASP output per cell). The product -- total SASP burden -- drops more than either intervention achieves alone.

Niedernhofer et al. (2024) published a framework paper arguing that optimal senescent cell management requires both approaches, calibrated to tissue type and disease context. Some tissues (adipose, liver) respond well to senolytics because senescent cells are accessible and clearance is well-tolerated. Other tissues (brain, heart) may benefit more from senomorphic approaches because cell loss in non-regenerative tissues carries higher risk (Nature Reviews Drug Discovery, 2024).

Tissue-Specific Considerations

Not all senescent cells are created equal, and not all tissues respond the same way to clearance:

• Adipose tissue: High senescent cell burden, excellent regenerative capacity. Senolytics work well here -- fat tissue can easily replace lost cells.
• Liver: High regenerative capacity. Senolytic clearance is generally well-tolerated.
• Brain: Minimal regenerative capacity. Senescent astrocytes and microglia contribute to neuroinflammation, but killing neurons (even damaged ones) carries risk. Senomorphics may be preferred for CNS applications.
• Heart: Cardiomyocytes (heart muscle cells) have extremely limited regenerative capacity. Senescent cardiomyocytes should probably be suppressed rather than killed.
• Cartilage: Senescent chondrocytes drive osteoarthritis. Cartilage has minimal regeneration. The D+Q trial for knee osteoarthritis is testing whether local senolytic benefit outweighs the regeneration concern.
• Eyes: The Unity UBX1325 trial demonstrates that local senolytic delivery to the retina can work for degenerative conditions -- the eye is an immunologically privileged site where senolytic clearance is relatively safe.

Safety Note: Dasatinib (used in D+Q senolytic protocols) is a prescription chemotherapy drug with significant side effects including fluid retention, bleeding risk, and immunosuppression. The D+Q senolytic protocol requires physician oversight. Supplement-accessible senolytics (fisetin, quercetin) are safer but should still be discussed with your doctor if you take blood thinners or immunosuppressants.

Key Takeaway: The emerging consensus is that senolytics and senomorphics work best in combination — periodic senolytic pulses (fisetin/quercetin) to reduce the senescent cell burden, combined with daily senomorphics (apigenin) to suppress SASP from the remaining cells. This dual approach addresses both the source (cells) and the signal (SASP) of senescence-driven aging.

Practical Protocol Considerations

Senolytic Pulse Dosing: The Kirkland Protocol

Dr. James Kirkland's Mayo Clinic research established the foundational pulse-dosing framework for senolytics:

• Frequency: 2 consecutive days per month (sometimes described as 2 days on, 28 days off)
• Rationale: Senescent cells accumulate slowly -- weeks to months for a clinically meaningful new cohort. A brief, high-dose pulse clears the existing population. Then you wait.
• Key principle: "Hit-and-run" -- the drug does not need to be present continuously because the effect (cell death) is permanent

The D+Q human trials use dasatinib 100 mg + quercetin 1,000 mg for 3 consecutive days. The fisetin AFFIRM-LITE trial uses 20 mg/kg for 2 consecutive days. Both follow the pulse framework.

The advantage of pulse dosing: lower cumulative drug exposure, fewer side effects, no development of tolerance. The disadvantage: you need confidence that the senolytic is actually clearing cells during each pulse, which requires biomarker monitoring that is not yet routine.

Senomorphic Daily Dosing

Senomorphics are dosed differently because they work differently:

• Rapamycin: Typically studied at 1-6 mg once weekly (not daily) in aging contexts. Weekly dosing preferentially inhibits mTORC1 (beneficial) while allowing mTORC2 (needed for insulin signaling) to recover between doses.
• Metformin: 500-2,000 mg daily, the same dose range used for diabetes. The TAME trial uses 1,500 mg daily.
• Apigenin: Studied at 50-100 mg daily in preclinical senomorphic research. Human dosing is not yet established for this indication.

The key difference from senolytics: senomorphics must be present continuously to work. Miss a week of rapamycin, and the SASP comes back. Miss a month of senolytics, and nothing changes -- the cells you killed are still dead.

What Monitoring Looks Like

Regardless of approach, tracking efficacy requires measuring senescence and SASP markers:

• p16^INK4a and p21: Senescence biomarkers. Elevated levels indicate senescent cell burden. Senolytics should reduce them; senomorphics should not (they leave cells alive).
• IL-6 and TNF-alpha: SASP cytokines. Both senolytics and senomorphics should reduce circulating levels.
• hs-CRP (high-sensitivity C-reactive protein): An accessible marker of systemic inflammation driven partly by the SASP.
• SA-beta-galactosidase: A histological marker of senescence (an enzyme that accumulates in senescent cells and can be detected in tissue samples). Used in research but not routine clinical testing.
• GDF-15 (Growth Differentiation Factor 15): An emerging blood biomarker of cellular stress and senescence, increasingly available in consumer blood panels.

The honest state of the field: we do not yet have a simple blood test that reliably quantifies senescent cell burden. p16 mRNA in blood T cells is the closest, but standardization and widespread availability are still developing. This is one of the field's most important gaps.

Frequently Asked Questions

Q: Can senolytics and senomorphics be used together?

Yes, and this is the direction the field is heading. The emerging framework combines periodic senolytic pulses (to clear accumulated senescent cells) with continuous senomorphic use (to suppress SASP from remaining and newly formed cells). The approaches target different mechanisms and are mechanistically complementary.

Q: Which approach is safer?

Senomorphics generally have more established safety data because the leading compounds (metformin, rapamycin) have decades of clinical use for other indications. Senolytics are newer and have less human safety data, particularly at the high pulse doses used for senolytic effect. However, the pulse-dosing pattern of senolytics means lower cumulative exposure than daily senomorphics.

Q: If I only had to choose one approach, which is better?

It depends on your situation and goals. For reducing existing senescent cell burden -- for example, in someone older with likely high accumulation -- senolytics offer more definitive benefit. For ongoing SASP suppression and inflammation management, senomorphics provide continuous coverage. Most researchers in the field believe neither approach alone is optimal.

Q: Are there natural senomorphics?

Yes. Apigenin (found in chamomile, parsley, celery) has demonstrated NF-kB-mediated SASP suppression in preclinical studies. Resveratrol has senomorphic properties through SIRT1 activation and NF-kB inhibition. EGCG from green tea has shown SASP suppression in cell culture studies. These are less potent than pharmaceutical senomorphics but have better safety profiles for long-term daily use.

Q: Does exercise have senolytic or senomorphic effects?

Both. Acute exercise transiently activates immune cell-mediated clearance of senescent cells (a mild senolytic effect). Regular exercise also reduces circulating SASP markers (a senomorphic effect). The IL-6 released during exercise -- paradoxically an anti-inflammatory signal in this context -- helps coordinate both processes (Schafer et al., Aging Cell, 2022). For more on the exercise-longevity connection, see Exercise and Longevity: What Actually Works.

Q: What is the SASP exactly, and why can't the immune system just handle it?

The SASP is a collection of 40-80 secreted molecules produced by senescent cells, including pro-inflammatory cytokines (IL-6, IL-1beta, TNF-alpha), chemokines (IL-8, MCP-1), growth factors (VEGF, TGF-beta), and matrix-degrading enzymes (MMPs). In youth, the immune system efficiently clears senescent cells before the SASP causes systemic problems. With age, immune surveillance declines (a process called immunosenescence -- the gradual deterioration of the immune system with age), senescent cells accumulate faster than they are cleared, and the cumulative SASP output overwhelms the system. The SASP itself further impairs immune function, creating a vicious cycle.

Q: Will insurance cover senolytic or senomorphic treatments?

Currently, no insurance covers these treatments specifically for aging. Metformin is inexpensive and covered for diabetes. Rapamycin is covered for transplant patients. Ruxolitinib is covered for myelofibrosis. If the TAME trial succeeds and the FDA accepts aging as a treatable condition, the coverage landscape could change substantially.

The Bottom Line: Neither killing nor silencing zombie cells alone is the complete answer -- the emerging science points to combining periodic senolytic pulses with daily senomorphic maintenance as the most effective strategy against senescence-driven aging.

Related Reading

• Senescent Cells Explained: The Zombie Cells Aging You Faster
• Fisetin: The Most Potent Natural Senolytic Compound
• Inflammaging: The Chronic Inflammation That Drives Every Aging Hallmark
• Apigenin: CD38 Inhibitor, Sleep Support, and NAD+ Protector
• The 12 Hallmarks of Aging: Why You Age and What Targets Each One
• Rapamycin: The Most Studied Anti-Aging Drug in History

Citations:

• Zhu Y et al. The Achilles' heel of senescent cells. Aging Cell. 2015. PMID 25754370
• Zhu Y et al. Identification of a novel senolytic agent, navitoclax. Aging Cell. 2016. PMID 26711051
• Yousefzadeh MJ et al. Fisetin is a senotherapeutic. EBioMedicine. 2018. PMID 30279143
• Hickson LJ et al. Senolytics decrease senescent cells in humans. EBioMedicine. 2019. PMID 31542391
• Baker DJ et al. Naturally occurring p16-positive cells shorten healthy lifespan. Nature. 2016. PMID 26840489
• Baar MP et al. Targeted apoptosis of senescent cells restores tissue homeostasis. Cell. 2017. PMID 28340339
• Acosta JC et al. A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Cell. 2013. PMID 23540693
• Laberge RM et al. mTOR regulates the SASP through NF-kB. Nature Cell Biology. 2015. PMID 26147250
• Moiseeva O et al. Metformin inhibits the SASP. Aging Cell. 2013. PMID 23834033
• Lim H et al. Effects of flavonoids on SASP. J Cell Physiol. 2015. PMID 25303541
• Xu M et al. JAK inhibition alleviates age-related dysfunction. Aging Cell. 2015. PMID 26166558
• Xu M et al. Senolytics improve physical function and increase lifespan. Nature Medicine. 2018. PMID 29988130
• Mannick JB et al. mTOR inhibition improves immune function in the elderly. Science Translational Medicine. 2014. PMID 25540326
• Mannick JB et al. TORC1 inhibition enhances immune function. Science Translational Medicine. 2018. PMID 30068573
• Demaria M et al. Senescent cells promote tissue repair. Developmental Cell. 2014. PMID 25449471
• Tuttle CSL et al. Cellular senescence markers in peripheral blood T cells. Aging Cell. 2020. PMID 31560839
• Niedernhofer LJ et al. Senotherapeutics for healthy ageing. Nature Reviews Drug Discovery. 2024

These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.